Pain & Inflammation
Clinical positioning
Lower concentration cannabinoid-rich oil for inflammatory pain and mobility-support discussions.
Clinical use lens
Inflammation-first entry oilA practical starting choice when pain is linked with stiffness, inflammatory tone or mobility limitation.
Protocol mapping
Indication fit
Inflammatory pain
Osteoarthritis
Myofascial pain
Mobility support
Why doctors reach for it
Clinical highlights
✦Inflammatory pain: lower-strength cannabinoid oil for titration
✓Mobility support: osteoarthritis, myofascial and soft-tissue discomfort contexts
→Carrier logic: coconut/MCT base supports absorption of lipophilic actives
How it is positioned to work
Mechanism map
1CB1/CB2 oriented endocannabinoid-system support
2Anti-inflammatory mediator balance and TRPV1 pain-signalling support
3MCT/coconut oil carrier improves solubilisation of lipophilic actives
Physician-directed dosing
Administration & dosing
X
Dose framework
X = body weight in kilogramsFirst dose
≤ X/2 mgGrade-guided range
X–10X mg
≤ X/2 mgGrade-guided range
X–10X mg
First dose must never exceed X/2 mg total cannabinoids (equivalent to ≤0.5 mg/kg when X is body weight in kg). Further titration may move within X to 10X mg total cannabinoids only after tolerance and response review.
1–10
Indication grade
- Grade 1–10: set by indication severity, pain/inflammation burden, ESR, CRP and symptom trajectory.
- Adjust for age, frailty, secondary conditions, hepatic/renal risk, concurrent medicines and tolerance.
- Use follow-up response to hold, increase, reduce or discontinue.
↗
Titration model
- Incremental: gradual upward titration until response / tolerability.
- Incremental–decremental: step up, then reduce to minimum effective maintenance.
- Microdosing: very low divided exposure for sensitive, elderly or polypharmacy patients.
Rx
Administration
- Oral / sublingual / with suitable carrier as per physician direction and product format.
- Prefer consistent timing; document relation to food, sleep, pain peak, appetite or protocol goal.
- Document dose, route, time, food/carrier, indication grade, ESR/CRP or relevant markers, adverse effects and follow-up plan.
- Monitor sedation, dizziness, GI tolerance, cognition, drug interactions and functional response.
Full titration walkthrough: physician dosage guide.
In-clinic use
Doctor use notes & safety boundary
Doctor use notes
- Start low and titrate by clinical context, tolerability and symptom severity.
- Track response, co-medications, sedation, GI tolerance and follow-up outcome.
- Document dose, timing, duration, indication and review plan.
Safety boundary
- For registered medical practitioners only
- Select dose by clinical context and tolerability
- Monitor sedation, interactions and follow-up response
- Not for direct patient promotion
2 actives
Formula / ingredients
| Ingredient | Botanical / base | Part | Qty |
|---|---|---|---|
| Vijaya leaves | Cannabis Sativa Linn | Leaves | 10% |
| Coconut Oil | Cocos Nucifera | — | 90% |
Clinic packs
Pack / MRP
| Pack | Strength | MRP |
|---|---|---|
| 10 ml (1 g) | 1000mg total cannabinoids≈ 5 mg/drop | ₹550 |
| 30 ml (3 g) | 3000mg total cannabinoids≈ 5 mg/drop | ₹1,299 |
Pack / MRP summary: 10 ml (1 g) ₹550 (1000mg) · 30 ml (3 g) ₹1,299 (3000mg)
4 source links
Audited research links
| Audited reference fit | Clinical logic | Source |
|---|---|---|
| CBD / cannabinoids ✓ Pain/inflammation checkedPMC full textScientific context Cannabidiol as a Treatment for Arthritis and Joint Pain | Arthritis and joint pain research support | Open ↗ |
| CBD ✓ Pain/inflammation checkedPMC full textMechanistic rationale CBD for Pain Treatment: Focus on Pharmacology and Mechanism of Action | Pain pharmacology and CB2/TRPV1/5-HT1A mechanisms | Open ↗ |
| Cannabis active compounds ✓ Pain/inflammation checkedPMC full textMechanistic rationale Medical Cannabis Activity Against Inflammation: Active Compounds and Mechanisms | Anti-inflammatory active-compound mechanisms | Open ↗ |
| MCT / lipid carrier ✓ Scientific fit checkedPMC full textScientific context Inclusion of Medium-Chain Triglyceride in Lipid-Based Formulations for Cannabidiol | CBD/MCT lipid-formulation and carrier-solubilisation context | Open ↗ |
Educational use only. Doctor-facing scientific aid only. Research links are mapped for ingredient rationale, mechanism, clinical context and safety boundaries. This brochure does not replace diagnosis, standard-of-care treatment, regulatory prescribing rules or clinical monitoring. See our legal & medical disclaimer and editorial policy.
Same protocol
